MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer

Fujishima,Yuka; Goi,Takanori; Kimura,Youhei; Hirono,Yasuo; Katayama,Kanji; Yamaguchi,Akio

doi:10.3892/ijo.2012.1334

MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer

Authors:
- Yuka Fujishima
- Takanori Goi
- Youhei Kimura
- Yasuo Hirono
- Kanji Katayama
- Akio Yamaguchi
View Affiliations

Affiliations: First Department of Surgery, University of Fukui, 23-3 Eiheiji-cho, Yoshida-gun, Fukui, Japan, First Department of Surgery, University of Fukui, 23-3 Eiheiji-cho, Yoshida-gun, Fukui, Japan
Published online on: January 16, 2012 https://doi.org/10.3892/ijo.2012.1334
Pages: 960-964

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We conducted a molecular biological investigation to determine the outcomes of hyperthermic intraperitoneal chemotherapy (HIPEC) treatment, and whether it is effective in all cases for patients with peritoneal dissemination of colon cancer. In the HIPEC group, the 3-year survival rate was 39.2%, whereas in the non-HIPEC group the 3-year survival rate was 15.6%. MUC2 expression was investigated in the HIPEC group, in patients positive for MUC2 expression, and the 3-year survival rate was 0.0%, while in patients negative for MUC2 expression, the 3-year survival rate was 61.1%. In addition, as a result of introducing MUC2-siRNA into a colon cancer cell line with high expression of the MUC2 gene, the cell death rate from heat and anticancer agents increased 40% in comparison with colon cancer cells in which scrambled siRNA had not been introduced. HIPEC therapy is thought to be effective in prolonging survival in patients with peritoneal dissemination of colon cancer, and MUC2 expression is thought to be useful as an indicator to assess its effectiveness in colon cancer cells.

View Figures

View References

1	Tominaga S and Oshima A: Cancer Mortality and Morbidity statistics. Japan and the World-1999. Gann Monograph on Cancer Research No. 47. Japan Scientific Societies Press; Tokyo, Japan: 1999
2	Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
3	Jayne DG, Fook S, Loi C and Seow-Choen F: Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 89:1545–1550. 2002. View Article : Google Scholar : PubMed/NCBI
4	Rampone B, Schiavone B, Martino A and Confuorto G: Current role of hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from colorectal cancer. World J Gastroenterol. 16:1299–1302. 2010. View Article : Google Scholar : PubMed/NCBI
5	Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M and Rat P: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 22:3284–3292. 2004. View Article : Google Scholar
6	Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA and Levine EA: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 11:178–186. 2004. View Article : Google Scholar
7	Sugarbaker PH: Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 14:254–261. 1998. View Article : Google Scholar : PubMed/NCBI
8	Chua TC, Morris DL and Esquivel J: Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 17:1330–1336. 2010. View Article : Google Scholar
9	Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-Margoulis O, Schmitz-Madry A, Zahn A, Stremmel W and Schmitz G: Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med. 84:1055–1066. 2006. View Article : Google Scholar : PubMed/NCBI
10	Itoh Y, Kamata-Sakurai M, Denda-Nagai K, Nagai S, Tsuiji M, Ishii-Schrade K, Okada K, Goto A, Fukayama M and Irimura T: Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucin. Glycobiology. 18:74–83. 2008. View Article : Google Scholar : PubMed/NCBI
11	Knowles MR and Boucher RC: Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 109:571–577. 2002. View Article : Google Scholar : PubMed/NCBI
12	Takeyama K, Dabbagh K, Lee HM, Agusti C, Lausier JA, Ueki IF, Grattan KM and Nadel JA: Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci USA. 96:3081–3086. 1999. View Article : Google Scholar : PubMed/NCBI
13	Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, Büller HA, Dekker J, Van Seuningen I, Renes IB and Einerhand AW: Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 131:117–129. 2006.PubMed/NCBI
14	Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K and Augenlicht L: Colorectal cancer in mice genetically deficient in the mucin Muc2. Science. 295:1726–1729. 2002. View Article : Google Scholar : PubMed/NCBI
15	Allen A, Hutton DA and Pearson JP: The MUC2 gene product: a human intestinal mucin. Int J Biochem Cell Biol. 30:797–801. 1998. View Article : Google Scholar : PubMed/NCBI
16	Byrd JC and Bresalier RS: Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 23:77–99. 2004. View Article : Google Scholar : PubMed/NCBI
17	Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal Carcinoma. 1st English edition. Kanehara Publishers; Tokyo: 1997
18	Katayama K, Yamaguchi A, Murakami M, Koneri K, Nagano H, Honda K, Hirono Y, Goi T, Iida A and Ito H: Chemo-hyperthermic peritoneal perfusion (CHPP) for appendiceal pseudomyxoma peritonei. Int J Clin Oncol. 14:120–124. 2009. View Article : Google Scholar : PubMed/NCBI
19	Dewey WC, Hopwood LE, Sapareto SA and Gerweck LE: Cellular responses to combinations of hyperthermia and radiation. Radiology. 123:463–474. 1977. View Article : Google Scholar : PubMed/NCBI
20	Yamaguchi A, Urano T, Goi T, Saito M, Takeuchi K, Hirose K, Nakagawara G, Shiku H and Furukawa K: Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol. 14:1122–1127. 1996.PubMed/NCBI
21	Goi T, Yamaguchi A, Nakagawara G, Urano T, Shiku H and Furukawa K: Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. Br J Cancer. 77:466–471. 1998. View Article : Google Scholar : PubMed/NCBI
22	Gum JR Jr, Hicks JW, Toribara NW, Siddiki B and Kim YS: Molecular cloning of human intestinal mucin (MUC2) cDNA. Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor. J Bio Chem. 269:2440–2446. 1994.
23	Pratt WS, Crawley S, Hicks J, Ho J, Nash M, Kim YS, Gum JR and Swallow DM: Multiple transcripts of MUC3: evidence for two genes, MUC3A and MUC3B. Biochem Biophys Res Commun. 275:916–923. 2000. View Article : Google Scholar : PubMed/NCBI
24	Ho SB, Roberton AM, Shekels LL, Lyftogt CT, Niehans GA and Toribata NW: Expression cloning of gastric mucin complementary DNA and localization of mucin gene expression. Gastroenterology. 109:735–747. 1995. View Article : Google Scholar : PubMed/NCBI